

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants:	Smith et al.	Examiner:	Unassigned
Application No.:	Unassigned	Group Art Unit:	Unassigned
Confirmation No:	Unassigned	Docket:	903-134 PCT/US
Filed:	Herewith	Dated:	May 6, 2005
For:	IMPROVED CROSSLINKED ENZYME AGGREGATES		

Confirmation No.: Unassigned

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Date May 6, 2005 Label No.: EV481314816US

I hereby certify that on the date indicated above I deposited this paper or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 by "EXPRESS MAIL POST OFFICE to ADDRESSEE" service.

Signed: Barbara Thomas/ 

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicants submit herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98. The documents are listed on PTO Form 1449. We have enclosed the cited documents, except for the cited U.S. Patents and U.S. Patent Application Publications as the U.S. Patent Office has waived paper submission thereof, to facilitate reference to them.


Enclosed is a copy of the International Search Report for PCT/EP03/012794 and for priority application EP 02079675.1. Except as being cited in the above-mentioned reports, the exact relevance of certain references is unknown.

Also included is a copy of the written opinion and the International Preliminary Examination Report for PCT/EP03/012794.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication, or credit any overpayment, to Deposit Account No. 08-2461. Such authorization includes authorization to charge fees for extensions of time, if any, under 37 C.F.R. § 1.17 and also should be treated as a constructive petition for an extension of time in this reply or any future reply pursuant to 37 C.F.R. § 1.136.

If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicants' attorney at the telephone number set forth below.

Respectfully submitted,



Christina L. Warrick  
Registration No.: 45,690  
Attorney for Applicant(s)

HOFFMANN & BARON, LLP  
6900 Jericho Turnpike  
Syosset, New York 11791  
(516) 822-3550

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)	ATTY. DOCKET NO. 903-134 PCT/US	SERIAL NO. Unassigned <b>10/534218</b>
	APPLICANT Smith et al.	CONFIRMATION NO. Unassigned
	FILING DATE Herewith	GROUP Unassigned

## U.S. PATENT PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
		EP 1 088 887 A1	04/04/01	EPO				
		WO 02/061067	08/08/02	PCT				
		DE 44 19 024 C1	10/19/95	Germany				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			Lopez-Serrano et al.; Cross-linked enzyme aggregates with enhanced activity: application to lipases; Biotechnology Letters; Vol. 24, No. 16; August 2002; pages 1379-1383.
--	--	--	--

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.